Large Cap Biopharmaceutical Valuations: Q1 2017

May 8, 2017  Large Cap Biopharma Valuations After Q1 Earnings

Large cap biopharmaceutical stocks are about 3-4% off their 2017 highs but have been losing momentum. Here is a quick review of the valuation metrics:

  • Best stock performance YTD are REGN up 15.3%, AMGN up 11.5% and ABBV up 5.73%.  The large cap focused IBB was up 9.07% .
  • Valuations that appear most attractive based on P/S are: ABBV, GILD. Both have attractive dividends.
  • Best growth prospects based on Q/Q are : ALXN, CELG, and REGN. All have a high Price/Sales ratio.
  • Best earnings prospects based on PEG and Q/Q are: ABBV,BMY and CELG.
  • Rayno Life Science Picks have been: ABBV, AMGN, BIIB, BMY, GILD and RHHBY(data not available).
Company Ticker Price 2017 Market P/S PEG Q/Q Q/Q Perform Price 5/8 % Perf DIV
1/7/2016 Rev$B Cap $B REV EPS %12 mos 2017 YTD
5/8/2017 Gr% Gr% 5/8/17
Abbvie ABBV 57.21 26.22 104.7 4 1.21 9.7 28.1 5.92 66.21 5.73 3.87
Alexion ALXN 174.37 3.25 28 8.61 3.17 24.1 85.2 -11.71 124.48 1.74
Amgen AMGN 158 22.93 120.15 5.24 2.83 -1.1 11.8 6.42 163.03 11.5 2.82
Biogen BIIB 284.01 11.53 55.81 4.84 2.02 3.1 -21.8 -1.21 260.42 -8.17
Bristol MyersSqibb BMY 65.27 19.97 91.31 4.57 2.08 12.3 32.4 -22.89 54.94 -6.02 2.84
Celgene CELG 111.89 11.68 92.2 7.9 2.15 17.9 17 18.1 118.36 2.25
Gilead Sci GILD 96.25 29.1 87.9 3.02 -16.5 -18.8 -20.6 67.21 -6.14 3.09
Regeneron REGN 501.96 4.86 42.17 8.68 2.97 9.8 36.2 14.44 423.38 15.33
IBB 304 8.18 13.39 289.45 9.07
XBI 61.82 2.75 35.52 68.25 15.31
FBIOX 8.88 13.84  195.65  15
FBT 21.14 104.97 15.5

, , , , , ,

No comments yet.

Leave a Reply